Randomized Clinical Study for Early Stage Prostate Cancer – Prostate Advances for Comparative Evidence (PACE)
Actively Recruiting Participating Centers
PACE is an international randomized study of low and intermediate risk organ-confined prostate cancer and is composed of two parallel randomization schemes. Patients for whom surgery is a consideration are randomized to either laparoscopic prostatectomy or CyberKnife® prostate stereotactic body radiotherapy (SBRT). Patients for whom surgery is not a consideration are randomized to either conventionally fractionated radiation therapy or CyberKnife® prostate SBRT. Efficacy, toxicity and quality of life outcomes will be compared. Study details can be found on www.clinicaltrials.gov (identifier number: NCT01584258). For more information, please email questions to PACE@accuray.com.